{"created":"2023-06-20T16:43:09.249002+00:00","id":13954,"links":{},"metadata":{"_buckets":{"deposit":"86c006c7-4e0d-45a5-ad1a-b6fdf0fd8044"},"_deposit":{"created_by":3,"id":"13954","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"13954"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00013954","sets":["14:2667:2671:2672"]},"author_link":["25619","25618","25617"],"item_8_alternative_title_3":{"attribute_name":"その他（別言語等）のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations."}]},"item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-01-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"4","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2013. )"}]}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文): ＥＧＦＲチロシンキナーゼ阻害剤によるアポトーシスにおいてｻﾊﾞｲﾋﾞﾝの発現低下が重要な役割を果たしていることをin vitro, in vivoにおいて証明した. そしてEGFR阻害剤に耐性を示すEGFR遺伝子変異陽性非小細胞肺癌株に対し, EGFR阻害剤であるエルロチニブとサバイビン阻害剤であるYM155の併用を行うことでその耐性を克服し, これらの細胞にアポトーシスを生じさせることができることをin vitro, in vivoにおいて証明した. これらの成果をもとにエルロチニブとYM155の併用療法がEGFR阻害剤の耐性を克服できる可能性を示した論文として海外雑誌に報告した.           研究成果の概要（英文): The molecular mechanism by which epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) induce apoptosis in non-small cell-lung cancer (NSCLC) cells that are positive for activating mutations of the EGFR remains unclear. In this study, we report the effects of the EGFR-TKI gefitinib on expression of the antiapoptotic protein survivin that have functional consequences in EGFR mutation-positive NSCLC cells. Immunoblot analysis revealed that gefitinib downregulated survivin expression, likely through inhibition of the PI3K-AKT signaling pathway, in NSCLC cells positive for EGFR mutation. Stable overexpression of survivin attenuated gefitinib-induced apoptosis and also inhibited the antitumor effect of gefitinib in human tumor xenografts. Our results indicate that downregulation of survivin plays a pivotal role in gefitinib-induced apoptosis in EGFR mutation-positive NSCLC cells.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：基盤研究(C);  研究期間：2011～2013;   課題番号：23501316;   研究分野：総合領域;   科研費の分科・細目：腫瘍学・臨床腫瘍学","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_relation_11":{"attribute_name":"著者 外部リンク","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"http://kaken.nii.ac.jp/d/r/90460865.ja.html"}]},{"subitem_relation_name":[{"subitem_relation_name_text":"http://kaken.nii.ac.jp/d/r/40298964.ja.html"}]},{"subitem_relation_name":[{"subitem_relation_name_text":"http://kaken.nii.ac.jp/d/r/10411597.ja.html"}]}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"},{"subitem_text_value":"研究分担者"},{"subitem_text_value":"研究分担者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"OKAMOTO, Kunio"},{"subitem_text_language":"en","subitem_text_value":"NAKAGAWA, Kazuhiko"},{"subitem_text_language":"en","subitem_text_value":"OKAMOTO, Isamu"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学医学部附属病院; 助教"},{"subitem_text_value":"近畿大学医学部; 教授"},{"subitem_text_value":"九州大学医学部; 准教授"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岡本,  邦男"},{"creatorName":"オカモト, クニオ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"中川,  和彦"},{"creatorName":"ナカガワ, カズヒコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岡本,  勇"},{"creatorName":"オカモト, イサム","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-03-31"}],"displaytype":"detail","filename":"KAKEN_23501316seika.pdf","filesize":[{"value":"90.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KAKEN_23501316seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/13954/files/KAKEN_23501316seika.pdf"},"version_id":"9778ae5d-6004-4906-8e5d-9085daa7e227"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"臨床腫瘍学","subitem_subject_scheme":"Other"},{"subitem_subject":"分子標的治療","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"ＥＧＦＲチロシンキナーゼ阻害剤によるアポトーシスにおけるサバイビンの役割","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ＥＧＦＲチロシンキナーゼ阻害剤によるアポトーシスにおけるサバイビンの役割"}]},"item_type_id":"8","owner":"3","path":["2672"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-10-16"},"publish_date":"2014-10-16","publish_status":"0","recid":"13954","relation_version_is_last":true,"title":["ＥＧＦＲチロシンキナーゼ阻害剤によるアポトーシスにおけるサバイビンの役割"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-20T23:06:42.274480+00:00"}